BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Cervical cancer AND KMT2D, ENSG00000167548, 8085, MLL2
29 results:

  • 1. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
    Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Mutational landscape of head and neck cancer and cervical cancer in Chinese and Western population.
    Li Q; Zhu G; Zhang L; Zeng B; Cai T; Wu J; Wei B; Xie Z; He L; Tang W; Lin X; Lu H; Wu F; Huang J; Hu H; Liu N; Fan S
    Head Neck; 2024 Mar; 46(3):528-540. PubMed ID: 38111234
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic cervical cancer: Genomic Profiling Relating to Clinical Efficacy.
    Zhang Q; Zhang J; Liu Z; Wang J; Wang F; Wang T; Shi F; Su J; Zhao Y
    Drug Des Devel Ther; 2023; 17():3507-3522. PubMed ID: 38046281
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Assessing the Genomic Landscape of cervical cancers: Clinical Opportunities and Therapeutic Targets.
    Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
    Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China.
    Liu J; Li Z; Lu T; Pan J; Li L; Song Y; Hu D; Zhuo Y; Chen Y; Xu Q
    BMC Med Genomics; 2022 Nov; 15(1):231. PubMed ID: 36333792
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
    Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
    BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Sodium Valproate Modulates the Methylation Status of Lysine Residues 4, 9 and 27 in Histone H3 of HeLa Cells.
    Rocha MA; de Campos Vidal B; Mello MLS
    Curr Mol Pharmacol; 2023; 16(2):197-210. PubMed ID: 35297358
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Characterization of the Genomic Landscape in cervical cancer by Next Generation Sequencing.
    Qiu L; Feng H; Yu H; Li M; You Y; Zhu S; Yang W; Jiang H; Wu X
    Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205332
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic cervical cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
    Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
    J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Can we reduce dose to ureters as avoidance organs for MRI based brachytherapy for cervical cancer? A dosimetric feasibility study.
    Koerner SA; Baig T; Kim H; Rodríguez-López J; Keller A; Beriwal S
    Brachytherapy; 2022; 21(2):202-207. PubMed ID: 34980569
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Basaloid Squamous Cell Carcinoma of the Uterine Cervix: Report of a Case With Molecular Analysis.
    Munkhdelger J; Shimooka T; Koyama Y; Ikeda S; Mikami Y; Fukuoka J; Hori T; Bychkov A
    Int J Surg Pathol; 2021 Oct; 29(7):770-774. PubMed ID: 33792431
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Update of the genotype and phenotype of kmt2d and KDM6A by genetic screening of 100 patients with clinically suspected Kabuki syndrome.
    Murakami H; Tsurusaki Y; Enomoto K; Kuroda Y; Yokoi T; Furuya N; Yoshihashi H; Minatogawa M; Abe-Hatano C; Ohashi I; Nishimura N; Kumaki T; Enomoto Y; Naruto T; Iwasaki F; Harada N; Ishikawa A; Kawame H; Sameshima K; Yamaguchi Y; Kobayashi M; Tominaga M; Ishikiriyama S; Tanaka T; Suzumura H; Ninomiya S; Kondo A; Kaname T; Kosaki K; Masuno M; Kuroki Y; Kurosawa K
    Am J Med Genet A; 2020 Oct; 182(10):2333-2344. PubMed ID: 32803813
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
    Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
    BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
    Park E; Kim SW; Kim S; Kim HS; Lee JY; Kim YT; Cho NH
    Mod Pathol; 2021 Mar; 34(3):637-646. PubMed ID: 32641744
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
    Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
    EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning.
    Huang J; Qian Z; Gong Y; Wang Y; Guan Y; Han Y; Yi X; Huang W; Ji L; Xu J; Su M; Yuan Q; Cui S; Zhang J; Bao C; Liu W; Chen X; Zhang M; Gao X; Wu R; Zhang Y; Xu H; Zhu S; Zhu H; Yang L; Xu X; Zhou P; Liang Z
    J Med Genet; 2019 Mar; 56(3):186-194. PubMed ID: 30567904
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in kmt2d mutants.
    Kalu NN; Mazumdar T; Peng S; Tong P; Shen L; Wang J; Banerjee U; Myers JN; Pickering CR; Brunell D; Stephan CC; Johnson FM
    Cancer Lett; 2018 Sep; 431():64-72. PubMed ID: 29807113
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Emerging role of mutations in epigenetic regulators including mll2 derived from The cancer Genome Atlas for cervical cancer.
    Li X
    BMC Cancer; 2017 Apr; 17(1):252. PubMed ID: 28390392
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.
    Pimenta JM; Galindo C; Jenkins D; Taylor SM
    BMC Cancer; 2013 Nov; 13():553. PubMed ID: 24261839
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.